2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

802. Chemical Biology and Experimental Therapeutics: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Apoptosis, CHIP, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS
PAPER

6080 Structure activity relationship of TET-inhibitor that selectively eliminates TET2 mutant cells

Anand Dev Tiwari, PhD, Mamta P Sumi, PhD2, Raziullah Khan Jr, PhD3, Aadvik Parhi4, Yihong Guan, PhD5, Dongxu Jiang, PhD6, Daniel J Vail, PhD7, Kacey O'Donnell8, Jaroslaw P. Maciejewski, MD, PhD, FACP9, Babal Kant Jha, PhD10
1 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States, Heart, Blood and Kidney Research, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
2 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
3 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
4 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
5 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
6 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
7 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
8 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
9 Heart, Blood and Kidney Research, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States
10 Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, United States

Background and Significance

TET enzymes (TET1-3) regulate promoter, enhancer and suppressor demethylation via progressive oxidation of 5-methylcytosine (5mC) that requires molecular oxygen, α-ketoglutarate (α-KG), iron (II) (Fe2+) and vitamin C as cofactors. This process is critical for transcription efficiency that determine lineage commitment, differentiation, proliferation and survival of hematopoietic stem and progenitor cells (HSPCs). Loss-of-function TET2 mutation (TET2MT) results in biased myeloid differentiation and is second most abundant lesion in clonal hematopoiesis of indeterminant potential (CHIP), a prodromal condition that increases the risk of developing frank leukemia and other related diseases.,  While the genetic loss of TET2 promotes myeloid neoplasia (MN), it also creates the vulnerability to malignant and pre-malignant TET2MT clones to further TET-inhibition due to its dependence on residual TET-activity. We have demonstrated that this residual TET-activity is essential for survival of TET2MT and TET-deficient cells., Here, we report a high throughput screening of TET inhibitors (TETi) and the structure activity relationships (SARs) of highly potent small molecule TETi that mimics loss of TET2 in TET proficient cells in-vitro and in-vivo and creates synthetic lethality to TET2MT HSPCs.

Study design and Methods

We developed a robust ELISA based high throughput screening assay for TET2 modulators and screened 43,000 bioactive drug libraries. The ‘Hit’ molecule, was further confirmed in three independent in-vitro assays. A SARs campaign was performed to generate low nanomolar efficacy TET inhibitor.

Results

We developed an ELISA based HTS assay utilizing biotinylated 5mC oligonucleotide substrate and probing 5-hydroxymethylcytosine (5hmC), a major TET dependent oxidation product by highly specific antibodies. The HTS was highly stable and robust as reflected in assay stability factors z’=0.6 and CV=6.8, in three independent assays in triplicates. The top ‘hits’ were selected based on z-score ≥3. The efficacy and specificity of lead compounds targeting TET-dioxygenase was evaluated in cell free and cell culture by measuring 5hmC. All co-factors as well as 5mC DNA substrates were competitively evaluated for TET inhibition. In addition, DNA intercalating properties of lead candidates were thoroughly evaluated.

Among the top “hit” molecules identified was Sepantronium bromide (YM155), previously been reported as a transcriptional regulator of survivin (BIRC5), a key regulator of apoptosis and cell-cycle progression in cancer. The mechanism of action of survivin inhibition has largely been unknown. We found that YM155 was active at the low nanomolar rage (IC50 ~2 nM) as inhibitor for the relative TET2 activity (5hmC/5mC). The transcriptional regulation of BIRC5 may be driven by promoter methylation because of TETi. Preincubation of inhibitors with DNA did not affect enzyme activity, ruling out the assumption that inhibitors may be a DNA intercalator or strongly bind to 5mC DNA. We synthesized a focused SAR library using TET2 binding site and confirm their specificity and activity. TETi works via direct binding to TET2, preventing substrate oxidation. The binding was independent of the cofactors (α-KG, Fe2+, Ascorbic acid) as 106-fold molar excess of these cofactors has no effect on TET-inhibitory activity. TETi induced synthetic lethality to TET2MT leukemic cells (IC50=2nM) while promoted the growth of normal HSPCs (2-fold over vehicle at 7.5nM) in colony forming assays. Consistent with our hypothesis, TET inhibitors mimics TET2 deficiency in TET2 proficient cells in vivo as observed intact homeostatic hematopoiesis and multilineage differentiation as observed in total blood counts of the animal treated with TETi.

Conclusion

Here we report that discovery of a highly potent TET-inhibitor that selectively eliminates TET2 mutant cells while phenocopying TET2 deficiency in TET2 proficient HSPCs under in-vitro and in-vivo conditions. This approach can be utilized to enhance homeostatic hematopoiesis and in eliminating TET2 mutant and TET-deficient clones at early as well as late malignant stages. TET inhibitor has dual effects; it restricts and eliminates TET2MT but expands normal HSPCs. Recent reports suggest that these inhibitors can be used for somatic cell reprograming to augment anticancer Immunotherapy.

Anand Dev Tiwari, PhD: No relevant conflicts of interest to declare.